Metabolomics and IDH1: Potential Therapeutic Targets to Block Glioma in Progression

Director of the renowned Abramson Cancer Center, Chi Van Dang, MD, PhD, reviews the role of isocitrate dehydrogenase 1 (IDH1) mutations in the aberrant metabolism of cancers, and their contribution to the gliomas. Beginning with the metabolism of cell growth and proliferation, Dr. Dang analyzes the metabolic impact of cancer-­associated IDH1 mutations in the gliomas and the effect of metabolic gene mutations on the metabolism of alpha­-ketoglutarate and its dependent enzymes. Finally, Dr Dang discusses current efforts to target and block the activity of ADH1 to halt the progression of the gliomas.